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Abstract
The role of c-Crk (CRK) in promoting metastasis is well described however the role of CRK phosphorylation and the
corresponding signaling events are not well explained. We have observed CRK-II serine 41 phosphorylation is inversely
correlated with p120-catenin and E-cadherin expressions in non-small cell lung cancer (NSCLC) cells. Therefore, we
investigated the role of CRK-II serine 41 phosphorylation in the down-regulation of p120-catenin, cell motility and cell
invasiveness in NSCLC cells. For this purpose, we expressed phosphomimetic and phosphodeficient CRK-II serine 41
mutants in NSCLC cells. NSCLC cells expressing phosphomimetic CRK-II seine 41 mutant showed lower p120-catenin level
while CRK-II seine 41 phosphodeficient mutant expression resulted in higher p120-catenin. In addition, A549 cells
expressing CRK-II serine 41 phosphomimetic mutant demonstrated more aggressive behavior in wound healing and
invasion assays and, on the contrary, expression of phosphodeficient CRK-II serine 41 mutant in A549 cells resulted in
reduced cell motility and invasiveness. We also provide evidence that PAK1 mediates CRK-II serine 41 phosphorylation. RNAi
mediated silencing of PAK1 increased p120-catenin level in A549 and H157 cells. Furthermore, PAK1 silencing decreased cell
motility and invasiveness in A549 cells. These effects were abrogated in A549 cells expressing phosphomimetic CRK-II serine
41. In summary, these data provide evidence for the role of PAK1 in the promotion of cell motility, cell invasiveness and the
down regulation of p120-catenin through CRK serine 41 phosphorylation in NSCLC cells.
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Introduction
Development of metastatic lesions in most solid tumors result in
an incurable condition by today’s treatment modalities. Therefore,
understanding the events that promote tumor invasion and
metastasis will help us prevent the spread of malignant tumors
especially in case of early stage and perhaps oligometastatic
disease. As a member of adherens junction, p120-catenin
(p120ctn) plays an important role in cell-cell adhesions and loss
of p120-catenin expression results in destabilization of the
cadherin-catenin complex thereby promoting tumor invasion
and metastasis [1,2,3,4,5,6,7,8,9,10]. Considering downregulation
of p120-catenin in non-small cell lung cancer (NSCLC) is
transcriptionally mediated [11], an investigation in the upstream
signaling events that could result in transcriptional repression of
p120-catenin (CTNND1), lead us to adaptor protein CRK and its
role in the repression of p120-catenin [12].
c-Crk (CRK) belongs to a family of widely expressed adaptor
proteins that are involved in signal transduction from a variety of
receptors and oncoproteins (e.g., Bcr-Abl; Tel-Abl, Erythropoietin
receptor, EGFR, GM-CSF, Insulin receptor substrate, PDGF and
VEGFR [13,14]). CRK, interacts with several downstream
effectors including SOS1, DOCK1 JNK1 and SP1. Our data
show that CRK negatively regulates p120-catenin (CTNND1)
transcription in NSCLC cells through interaction with transcrip-
tion factor SP1 [12]. The central position of CRK in signaling
cascades makes it likely that CRK affects several downstream
targets, other than the p120-catenin (CTNND1) promoter, thereby
promoting tumor progression, invasion and metastasis.
In addition to CRK overexpression as a proto-oncogene and its
role in cell transformation, CRK phosphorylation is also apt to
contribute to its biochemical activity. As an adaptor protein, CRK
does not contain a catalytic domain however both tyrosine and
serine kinase activities have been associated with CRK [15].
Proteins with phosphorylated tyrosine, serine or threonine residues
were detectable in the immunoprecipitate of CRK in avian
sarcoma virus (CT10) infected cells [15]. In this study, the product
of CT10 virus (p47gag-crk) itself was also highly phosphorylated
mainly on serine and about five percent on tyrosine residues.
Several intracellular signaling pathways contribute to CRK
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phosphorylation. For example, c-Abl phosphorylates Crk on
tyrosine 221 causing disassociation of Crk from the Crk-associated
substrate (CAS) thereby inhibiting cell migration and promoting
apoptosis in normal and malignant cells [16,17]. Abl has a critical
function in the formation and maintenance of adherens junctions
as was shown in mouse embryonic fibroblasts [18,19]. This effect
of Abl on adherens junctions seems to be mediated via the Crk and
Rac1 pathway that regulate cadherin-catenin adhesion complex.
These findings are pointing to the fact that CRK phosphorylation
plays an important role in cell motility and metastasis promotion.
With regards to CRK serine phosphorylation, two serine/
threonine kinases, [i.e., hematopoietic progenitor kinase 1 (HPK1;
MAP4K1) and kinase homologous to SPS1/STE20
(KHS;MAP4K5)], members of PAK serine/threonine kinase
super family, are known to mediate phosphorylation of CRK
family members and possibly participate in CRK mediated JNK
activation [20,21]. P21-activated kinases (PAKs) are well-known
regulators of cytoskeletal remodeling and cell motility and it seems
that PAK kinases play a role in metastatic promotion in malignant
tumors [22]. For example, endogenous PAK is constitutively
activated in certain breast cancer cell lines [23] and ectopic
expression of constitutively activated PAK1 in nonmetastatic
MCF-7 breast carcinoma cells increased cell motility [24]. In
addition, overexpression of PAK1 was recently reported in
NSCLC, mostly in squamous cell histology [25]. The above
mentioned strongly suggest a role for CRK serine phosphorylation
in metastatic promotion of malignant tumors. Biochemical
pathways that regulate CRK serine phosphorylation and the role
of CRK serine phosphorylation in metastasis promotion are not
well studied to date. Here we provide evidence that PAK1 kinase
mediates CRK-II serine 41 phosphorylation thereby promoting
cell motility and invasiveness in NSCLC cells.
Results
CRK-II Serine 41 Phosphorylation is Inversely Correlated
with p120-catenin Expression
We recently reported that CRK mediates transcriptional
repression of p120-catenin (CTNND1) in NSCLC cells. CRK can
be phosphorylated in both tyrosine and serine residues, which then
influences its interaction with downstream targets [15,16,26,27].
Therefore, we sought to further investigate whether CRK
phosphorylation status, as a surrogate of activated upstream
signals, is possibly playing a role in CRK mediated p120-catenin
(CTNND1) transcriptional repression. A close correlation of either
serine or tyrosine CRK phosphorylation with p120-catenin
expression would indicate the presence of an upstream serine/
threonine or a tyrosine kinase that would mediate CRK
phosphorylation thereby p120-catenin downregulation. For this
purpose, we examined the phosphorylated CRK-II level both on
tyrosine 221 and serine 41 and correlated that with p120-catenin
levels in a panel of NSCLC and BEAS-2B cells (Figure 1). In case
of tyrosine 221, phosphorylation of this residue by c-Abl is
reported to result in cell migration inhibition. We observed an
inverse correlation between phospho-serine 41 CRK-II with that
of p120-catenin and E-cadherin protein levels by western blotting.
Interestingly, phosphorylation of CRK-II on Y221 did not
correlate with p120-catenin expression. These findings suggest
that signaling events that engage serine/threonine kinases are
involved in p120-catenin (CTNND1) transcriptional downregulation
through serine phosphorylation of the CRK adaptor protein.
CRK-II Serine 41 Phosphorylation Regulates p120-catenin
Expression
In order to further assess the role of CRK serine 41
phosphorylation in the transcriptional regulation of p120-catenin
(CTNND1), we decided to examine whether CRK-II serine 41
manipulations might have any effect on the p120-catenin
expression level. Therefore, we proceeded to prepare CRK-II
serine 41 phosphodeficient and phosphomimetic mutants. A site
directed mutagenesis reaction was utilized to replace CRK-II
serine 41 with either Glycine [Ser41Gly (phosphodeficient)] or
Aspartic acid [Ser41Asp (phosphomimetic)]. A CRK-II construct
fused with a Myc-tag was used as the backbone of the site directed
mutagenesis reactions therefore, all resulting mutants contained a
Myc tag as well. All constructs were checked by sequencing.
Subsequently, A549, Rh2 and H157 cells were transiently
transfected with the resulting CRK-II mutants and we measured
the p120-catenin (CTNND1) promoter activity as well as p120-
catenin protein level by western blotting in the transfected cells.
The expression levels of CRK-II mutants and the endogenous
CRK-II are presented in (Figure S1). Compared to cells that
expressed wild type CRK-II, a significant increase in p120-catenin
(CTNND1) promoter activity was observed in cells expressing
phosphodeficient CRK-II. On the other hand, a decrease in p120-
catenin (CTNND1) promoter activity was observed in cells
expressing phosphomimetic CRK-II serine 41 mutant (Figure 2).
p120-catenin protein level also changed following expression of
CRK-II mutants concordant to the observed changes in p120-
catenin promoter activity alterations in all cell lines. These findings
further emphasize in the role of CRK serine 41 phosphorylation in
transcriptional regulation of p120-catenin (CTNND1).
CRK-II Serine 41 Phosphorylation is Involved in NSCLC
Cell Motility and Cell Invasion
Even though we observed CRK-II serine 41 phosphorylation is
engaged in p120-catenin (CTNND1) transcriptional regulation, it is
not clear whether phosphorylation of CRK-II on serine 41 has any
other significant biological relevance. Since expression of CRK
has been associated with more aggressive NSCLC tumors [28], we
decided to examine the motile and invasive properties of A549
cells following manipulation of CRK-II serine 41 phosphorylation.
Therefore, we proceeded to prepared A549 cells that stably
express our CRK-II serine 41 mutants. A549 cells were chosen for
this experiment since they express relatively low level of
endogenous CRK-II. As described in the Material and Methods
section, A549 cells were transfected with CRK-II serine 41
phosphodeficient and phosphomimetic mutants and were selected
in the presence of G418. The pooled selected cells were used for
the subsequent wound healing and cell invasion assays. The
expression level of the mutant proteins were checked in a western
blot assay (Figure S2). Next, we used the resulting A549 cells that
stably expressed CRK-II serine 41 phosphodeficient and phos-
phomimetic mutants in wound healing and Matrigel cell invasion
assays as explained in the Material and Methods section (Figure 3).
As expected, compare to A549 cells expressing empty vector, wild
type CRK-II expressing cells showed a more aggressive behavior.
Interestingly, A549 cells expressing CRK-II phosphodeficient
(Ser41Gly) mutant had a less motile property, almost similar to
empty vector group and cells expressing phosphomimetic (Ser41-
Asp) mutant had the most aggressive behavior in the wound
healing assays. We silenced the endogenous CRK by siRNA in all
conditions in order to reduce the interference of the endogenous
CRK with CRK-II mutant proteins (Figure S2). The siRNA that
was used for silencing the endogenous CRK was directed against a
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sequence outside CRK’s open reading frame therefore this siRNA
had no effect on the expression of CRK mutants by plasmid
constructs. A wider view of this wound healing assay and the
Matrigel membranes are presented in (Figures S3,S4). Similar to
the wound healing assays, A549 cells expressing CRK-II serine 41
phosphodeficient mutant had less invasiveness compared to cells
expressing empty vector and cells expressing CRK-II serine 41
phosphomimetic mutant had the most invasive property at 24
hours. Even though the endogenous CRK-II was incompletely
silenced among the groups, the ratio of CRK-II mutants to the
endogenous CRK-II was increased following silencing the
endogenous CRK. It is worth mentioning these biological effects
were not seen if the endogenous CRK was not silenced.
In order to examine whether changes in cell proliferation are
contributing to the observed biological behavior of the cell lines
with CRK-II mutants, cell proliferation rate of the resulting cell
lines were measured (Figure S5). Following plating equal number
of A549 cells transfected with CRK-II and CRK-II mutants, cells
were counted at 24 hour intervals. No significant difference in cell
numbers were noted among the groups. These observations
corroborate the involvement of CRK-II serine 41 phosphorylation
in the motility and invasiveness of NSCLC cells.
PAK1 kinase Mediates CRK-II Serine 41 Phosphorylation
Considering the role of CRK-II serine phosphorylation on
the p120-catenin (CTNND1) transcriptional repression and also
promotion of motility and invasiveness in NSCLC cells, we
sought to identify the upstream kinase(s) that might mediate
CRK-II serine 41 phosphorylation. CRK serine phosphorylation
has been reported by several members of the PAK serine/
threonine family of kinases [20,21]. For example, Hematopoietic
Progenitor Kinase 1 (HPK1; MAP4K1) and Kinase Homolo-
gous to SPS1/STE20 (KHS; MAP4K5) are reported to
phosphorylate CRK family members on serine residues.
Therefore, we decided to examine whether CRK-II serine 41
phosphorylation might be mediated by PAK family of kinases.
Towards this end, we chose to silence PAK1 by siRNA in
H157 and A549 NSCLC cells and examine CRK-II serine 41
phosphorylation by western blotting. Compared to cells treated
with non-silencing siRNA, PAK1 silencing lead to dramatically
reduced phospho-serine 41 CRK-II in both H157 and A549
cells (Figure 4C). Furthermore the amino acid sequence of
CRK-II within the vicinity of serine 41 matches with the known
PAK1 phosphorylation consensus sequences [29] (Figure 4D).
Notably, the RDSS amino acid sequence in CRK-II is identical
Figure 1. A- Western blots showing the expression pattern of p120-catenin, E-cadherin, CRK-I, CRK-II, phospho-serine 41 CRK-II and
phospho-tyrosine 221 CRK-II in a panel of NSCLC cells and BEAS-2B cells. B- Quantification of CRK-II, phospho-tyrosine 221 CRK-II and
phospho-serine 41 CRK-II signal intensity among NSCLC cell lines and BEAS-2B cells.
doi:10.1371/journal.pone.0042012.g001
Figure 2. A- Relative p120-catenin (CTNND1) promoter activity in A549, Rh2 and H157 cell lines following transient transfection of
CRK-II, CRK-II (Ser41Gly) or CRK-II (Ser41Asp) mutants. (2 tailed student’s t-test: * P,0.05; ** P,0.01; error bars represent 6 standard
deviation). B- Western blots showing changes in p120-catenin protein level in the above mentioned cell lines following transient transfection of CRK-II
and CRK-II mutants.
doi:10.1371/journal.pone.0042012.g002
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to the Pak1 phosphorylation sequence in Raf. These findings
Figure 3. A-Wound healing assays in A549 cells stably expressing pCMV vector, wild type CRK-II (WT), CRK-II (Ser41Gly) or CRK-II
(Ser41Asp) mutants. Endogenous CRK is silenced in all conditions by siRNA. B- Measurement of wound surface area 24 hours after establishment
of the wound among the above mentioned groups. The average is calculated following measurement of three separate experiments. (2 tailed
student’s t-test: ** P,0.01; *** P,0.001; error bars represent6 standard deviation).C- Invasion assays following incubation of stably transfected A549
cells expressing either pCMV vector; wild type CRK-II (WT); CRK-II (Ser41Gly) or CRK-II (Ser41Asp) mutants. 16105 cells were incubated over night as
described in the Methods section and stained at 24 hours after incubation. D- Quantitative measurement of the invaded cells. Five separate sections
of the invaded cells were counted. (2 tailed student’s t-test: ** P,0.01; *** P,0.001; error bars represent 6 standard deviation).
doi:10.1371/journal.pone.0042012.g003
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establish the role of PAK1 kinase as one of the kinases that
mediate CRK-II serine 41 phosphorylation.
PAK1 kinase Suppresses p120-catenin (CTNND1) Promoter
Activity and Expression Level
Considering the involvement of PAK1 kinase in mediating
CRK-II phosphorylation on serine 41 and also the role of CRK-
II serine 41 phosphorylation in p120-catenin (CTNND1) transcrip-
tional repression, we asked whether PAK kinases are in fact
involved in p120-catenin (CTNND1) repression. In order to verify
this notion, we silenced PAK1 and PAK2 by siRNA and
measured the p120-catenin (CTNND1) promoter activity in a dual
luciferase assay and also measured p120-catenin protein level by
western blotting (Figure 4). Following siRNA mediated silencing
of PAK1 in A549 cells, we observed more than 100% increase in
the luciferase activity of p120-catenin (CTNND1) promoter
reporter compared to cells transfected with non-silencing siRNA
(Figure 4A). Moreover, an increase in the p120-catenin protein
level was detected in H157 and A549 cells following siRNA
mediated PAK1 silencing (Figure 4C). We did not notice any
significant change in the p120-catenin (CTNND1) promoter
activity following siRNA mediated PAK2 silencing. These data
further institute a role for PAK1 in transcriptional regulation of
the p120-catenin (CTNND1).
Effects of PAK1 Kinase on p120-catenin (CTNND1)
Promoter Activity is Mediated through CRK-II Serine 41
Phosphorylation
To further establish a causal relationship between PAK1 and
CRK-II phosphorylation in p120-catenin expression, we decided
to examine the effect of simultaneous PAK1 and CRK-II serine
41 manipulations on the p120-catenin (CTNND1) transcriptional
regulation. Accordingly, we silenced PAK1 in A549 cells that
stably express CRK-II serine 41 phosphomimetic and phospho-
deficient mutants (Figure 5). We also silenced the endogenous
CRK by siRNA to reduce the unwanted interactions of the
endogenous CRK. As expected, A549 cells expressing wild type
CRK-II showed increased level of p120-catenin (CTNND1)
transcriptional activity following PAK1 silencing. This effect of
PAK1 on p120-catenin (CTNND1) transcriptional activity was
abrogated in cells expressing either phosphomimetic or
phosphodeficient CRK-II serine 41 mutants suggesting that
the inability of CRK-II to alter its phosphorylation status on
serine 41 (as a result of inserted mutations) abolishes the effect
of PAK1 on p120-catenin (CTNND1) transcription. These
findings further supports the role of CRK-II serine 41
phosphorylation on PAK1 mediated p120-catenin (CTNND1)
transcriptional regulation. The minor changes in the p120-catenin
(CTNND1) promoter activity that are observed in CRK-II serine
41 phosphomimetic mutant expressing cells (statistically non-
significant) could be as a result of the endogenous CRK-II
phosphorylation alteration following PAK1 silencing. It is worth
mentioning that RNAi mediated silencing of the endogenous
Figure 4. A-Relative p120-catenin (CTNND1) promoter activity in A549 cells following siRNA mediated silencing of PAK1 and PAK2. B-
Quantitative real time PCR measurement of PAK1 and PAK2 mRNA in order to determine the silencing efficiency of siRNA. C-Western blots showing
phospho-serine 41 CRK-II and p120-catenin expression following siRNA mediated PAK1 silencing in A549 and H157 cells. D- Pak1 phosphorylation
consensus sequence in several Pak1 substrates. Residues that are phosphorylated by Pak1 are highlighted in gray. Circled are the upstream arginine
residues that are important for Pak1 target phosphorylation.
doi:10.1371/journal.pone.0042012.g004
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CRK does not result is a complete knock down of the
endogenous CRK-II (Figure S2).
PAK1 Kinase Affects Cell Motility and Cell Invasiveness
through CRK-II Serine 41 Phosphorylation
Considering (i) CRK-II serine 41 phosphorylation promotes
cell motility and invasiveness and (ii) PAK1 mediates CRK-II
serine 41 phosphorylation, we were facing he question whether
PAK1 is indeed promotes cell motility and invasiveness through
CRK-II seine phosphorylation. To answer this question we
examined the motility and invasiveness of A549 cells following
simultaneous manipulations of PAK1 and CRK-II serine 41
phosphorylation (Figure 6). As expected, we observed a higher
motility and invasiveness of A549 cells expressing CRK-II serine
41 phosphomimetic mutant compared to cells expressing wild
type CRK-II. Following siRNA mediated silencing of PAK1,
cells expressing wild type CRK-II showed a diminished motility
and invasiveness. Interestingly, PAK1 silencing did not have any
effect on the motility and invasiveness of cells expressing CRK-II
serine 41 phosphomimetic mutant. Similar to other experiments,
the endogenous CRK was silenced by siRNA in all conditions in
order to reduce the interaction of endogenous CRK with CRK-
II phosphomimetic mutant. Therefore, we conclude that PAK1
effect on promoting cell motility and invasiveness is mediated
through CRK-II serine 41 phosphorylation.
Discussion
Understanding the signaling events that promote metastasis in
solid tumors will help us pin point therapeutic targets in order to
intervene in the metastasis process. Loss of cell-cell adhesions in
epithelial cells is one of the earliest steps of tumor spread.
Therefore, losing the integrity of adherens junction and its
members (i.e., cadherins and catenins) plays a pivotal role in the
promotion of metastasis. One of the frequent observed events in
NSCLC tumors is the p120-catenin downregulation. Since p120-
catenin repression in NSCLC is transcriptionally mediated [11],
we decided to further investigate the upstream signaling events
that eventually would lead to transcriptional repression of p120-
catenin (CTNND1). Through detailed analysis of the p120-catenin
(CTNND1) promoter, the role of transcription factors FOXC2 and
SP1 in the p120-catenin (CTNND1) downregulation were recog-
nized. Further analysis of the binding partners of SP1 lead us
identify the role of adaptor protein CRK in this pathway [12]
(Figure 7). Since CRK receives input from multiple signaling
pathways, it is likely that the upstream oncogenes that transmit
their respective signal through CRK have a significant impact on
the downregulation of p120-catenin, promotion of cell motility/
invasiveness and promotion of tumor metastasis. Therefore, as a
surrogate of activated upstream signals, we investigated the
phosphorylation status of CRK-II and noticed CRK-II serine 41
phosphorylation has an inverse correlation with the p120-catenin
Figure 5. Relative p120-catenin (CTNND1) promoter activity in A549 cells stably expressing wild type CRK-II (WT), CRK-II (Ser41Gly) or
CRK-II (Ser41Asp) mutants following siRNA mediated silencing of PAK1. Endogenous CRK is silenced in all conditions by siRNA. (2 tailed
student’s t-test: * P,0.05; error bars represent 6 standard deviation).
doi:10.1371/journal.pone.0042012.g005
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expression level in a panel of NSCLC cells. Of note, this
correlation was not observed with phosphorylation of CRK-II
on tyrosine 221. As an adaptor protein, CRK does not contain a
catalytic domain however both tyrosine and serine kinase activities
have been associated with CRK [15]. Our data show CRK-II
serine 41 phosphorylation manipulation alters the p120-catenin
(CTNND1) promoter activity, expression level and also the invasive
property of NSCLC cells.
Regarding CRK-I, it seems that higher expression of CRK-I
oncoprotein by itself is correlated with tumorigenesis. This
observation is in contrast with CRK-II where phospho-CRK-II
establishes a strong association with tumorigenesis. A significant
increase in CRK-I oncoprotein level and phosphorylated isoform
(CRK-II) were observed in NSCLC [28]. Similarly, here we
observe a close and inverse correlation between CRK-I expression
as well as phospho-serine 41 CRK-II with that of p120-catenin
and E-cadherin in our panel of NSCLC cells (Figure 1).
CRK serine phosphorylation is not well studied although there
are anecdotal reports regarding the role of PAK family of serine/
threonine kinases in CRK serine phosphorylation [20,21]. Here
we report the role of P21-activated kinase 1 (PAK1) in CRK-II
serine 41 phosphorylation thereby p120-catenin downregulation
and also promotion of cell motility and invasiveness in NSCLC
cells. PAK family of kinases are targets of GTP binding proteins
Cdc42 and Rac1 [30] and also are involved in cytoskeletal
reorganization. Involvement of PAK kinases in the promotion of
cell motility and cell shape are also well known [31,32]. PAK
kinases are classified in two major groups, group I (PAK1–3) and
group II (PAK4–6). This classification is mainly based on the
presence of an autoinhibitory region in group I PAK members
[33]. The role of group I PAKs is more clearly demonstrated in
cancer progression as PAK1 overexpression is seen is several
tumor types. PAK1 is overexpressed in breast, ovarian, lung and
head and neck cancers [25,34]. Additionally, PAK1 expression is
reportedly elevated in malignant progression of human colorectal
carcinoma [35]. Interestingly, PAK1 is also engaged in wound
healing and the regulation of contact inhibition in epithelial cells.
Following expression of activated PAK1 in MDCK epithelial
cells, a lack of growth arrest was observed upon wound closure
[36]. Here, we examined the role of PAK1 and PAK2 in CRK
mediated transcriptional regulation of p120-catenin (CTNND1)
and could only identify PAK1 as a regulator of p120-catenin
(CTNND1). PAK1 silencing reduced CRK-II serine 41 phos-
phorylation in A549 and H157 cells and enhanced p120-catenin
(CTNND1) promoter activity and protein level in NSCLC cells.
Additionally, PAK1 silencing reduced cell motility and invasive-
ness via CRK-II serine 41 phosphorylation.
PAK1 has a number of downstream targets that regulate actin
organization and polymerization, cell proliferation and apoptosis.
For instance, Pak1 interacts with filamin A and LIM kinase
[24,37] which inactivate the F-actin destabilizing protein cofilin,
leading to aggregation of F-actin fibers [38]. In addition to
regulating the cytoskeleton, PAK1 has an important role in
regulating activation of MAPK signaling pathways. Pak1 directly
activates Raf-1, by phosphorylating serine 338 [39] moreover
Pak1 directly activates MEK1, phosphorylating serine 298 [40].
Other than activating the ERK MAPK, overexpressed PAK1 has
been reported to activate p38 MAPKs [41,42] although the
details of this interaction are not well understood. PAK1 also
seems to be associated with JNK activity. Overexpression of Pak1
by different investigators has produced different reports indicat-
ing both enhanced [30,41,43] and impaired [44,45] JNK activity.
Furthermore, PAK1 has been reported to be a member of an
anti-apoptotic signaling network via its interactions with Bad
[46,47,48,49]. Data provided here introduce CRK-II as another
downstream target of PAK1. Considering CRK-II serine 41 is
part of a PAK1 phosphorylation consensus sequence (Figure 4D),
it is likely that PAK1 directly phosphorylates CRK-II on serine
41.
In summary, these data describe one of the metastatic
promoting pathways in NSCLC cells involving PAK1 kinase,
CRK-II, SP1 and p120-catenin. In other words, CRK-II
phosphorylation seems to play a part in conveying signals
downstream of PAK1. In conjunction with other report that
highlights PAK1 overexpression in squamous cell NSCLC [25,46],
it seems PAK1 inhibition might provide a viable strategy in order
to interrupt the pro-metastatic behavior of certain NSCLC
subtypes.
Figure 6. A-Wound healing assays in A549 cells stably expressing wild type CRK-II (WT) or CRK-II phosphomimetic (Ser41Asp)
mutants following siRNA mediated PAK1 silencing. Endogenous CRK is silenced in all conditions by siRNA. B- Measurement of wound surface
area 24 hours after the establishment of the wound among the above mentioned groups. The average is calculated following measurement of three
separate experiments. (2 tailed student’s t-test: ** P,0.01; *** P,0.001; error bars represent 6 standard deviation). C- Invasion assays following
incubation of stably transfected A549 cells expressing wild type CRK-II (WT) or CRK-II (Ser41Asp) mutant. Each cell line was treated with PAK1 siRNA or
scrambled sequence siRNA. 16105 cells were incubated over night as described in the Methods section and stained at 36 hours after incubation. D-
Quantitative measurement of the invaded cells. Five separate sections of the invaded cells in each Matrigel membrane were counted. (2 tailed
student’s t-test: ** P,0.01; *** P,0.001; error bars represent 6 standard deviation).
doi:10.1371/journal.pone.0042012.g006
Figure 7. Schematic view of PAK1, CRK-II and SP1 as well as
FOXC2 in transcriptional regulation of p120-catenin (CTNND1).
doi:10.1371/journal.pone.0042012.g007
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Materials and Methods
Cell Cultures
A549, H157, Rh2 and H358 cells were routinely cultured in
RPMI supplemented with antibiotics and 10% heat-inactivated
FBS (Omega Scientific, Tarzana, CA). Immortalized normal
human epithelial cells (BEAS-2B) were cultured in BEBM medium
supplemented with all the additives (Lonza/Clonetics Corpora-
tion, Switzerland; Catalog No. CC-3170).
Measurement of p120ctn Promoter Activity by Dual
Luciferase Assay
p120ctn promoter construct was transfected into NSCLC cell
lines by Lipofectamine 2000 (Invitrogen). Twenty-four hours after
transfection cells were washed with PBS and lysed using a Branson
Sonifier in 1x passive lysis buffer (Promega) at room temperature
(RT). Reporter gene expression was assessed by using the Dual-
Luciferase Reporter Assay System kit (Promega) according to
manufacturer’s instructions in a TD-20/20 Luminometer (Turner
Biosystems, Sunnyvale, CA). We normalized for transient trans-
fection efficiency (i.e. firefly luciferase activity) by co-transfection of
a Renilla luciferase expressing control vector (pRL-SV40). All
experiments were performed in triplicate and were reported as
means 6 standard deviation (SD), and each experiment was
performed at least twice.
siRNA Mediated Gene Silencing
A549 and H157 cells were transfected with siRNA against
CRK, PAK1 and PAK2. Transfections were performed by using
Lipofectamine 2000 (Invitrogen). The siRNA duplex sequences
that we used to silencing the above mentioned genes are as follows:
N CRK: 59-CUGCUUACCCUGAUUUAUUdtdt-39
59-AAUAAAUCAGGGUAAGCAUdtdt-39.
N PAK1: 59-GAAAGAGCGGCCAGAGAUUdtdt-39
59-AAUCUCUGGCCGCUCUUUCdtdt-39.
N PAK2: 59-GGAUUUCUUAAAUCGAUGUdtdt-39
59-ACAUCGAUUUAAGAAAUCCdtdt-39.
As a control, scrambled non-silencing siRNA was used (Sigma-
Aldrich Cat. number SIC002-10NMOL). Concentrations of
siRNA were kept at 100 nM among groups. In case of silencing
the endogenous CRK, the above siRNA is directed against CRK
mRNA in a region outside the open reading frame (approximate
siRNA start site 1210 based on reference NM_005206). Therefore
using this CRK siRNA has no effect on the CRK expressing
plasmids.
Measurement of mRNA Level by qRT-PCR
We used TaqMan probes and SYBR Green methods for
measurement of mRNA level following gene silencing. In case of
p120ctn, mRNA level in NSCLC cell lines were measured by
TaqMan probe; assay IDs: Hs00931670_m1 (Applied Biosystems,
Foster City, CA). For CRK, PAK1 and PAK2 we used SYBR
Green method with the following primers sets.
N PAK1-forward: 59-CGTGGCTACATCTCCCATTT-39
N PAK1-reverse: 59-TCCCTCATGACCAGGATCTC-39
N PAK2-forward: 59-GAAGAATCCTCAGGCTGTGC-39
N PAK2-reverse: 59-GGGTCACCTATGCTCACGAT-39
N CRK-forward: 59-GCAAGAGAGGGATGATTCCA-39
N CRK-reverse: 59-ATGGGAAGTGACCTCGTTTG-39
N Actin-forward: 59-TGACGGGGTCACCCACACTGTGCC-
CATCTA-39
N Actin-reverse: 59-CTAGAAGCATTTGCGGTGGACGAT-
GGA-39
In each cell type, total RNA was extracted by using Trizol
method and cDNA was prepared by an RT-PCR reaction using
SuperScript-II RT Kit (Invitrogen) and Oligo (dT)s according to
the manufacturer’s instructions. For each cDNA sample an
internal control (beta actin) was also measured by TaqMan probe.
In order to compare the expression level of mRNA between
samples, we used the Comparative Ct Method (DDCt). Relative
expression of mRNA compared to beta actin in each sample was
calculated (DCt) and relative expression of mRNA among samples
was determined by calculating the difference in (DCt) between
samples (DDCt). All relative quantitative PCRs were performed,
recorded, and analyzed by using the ABI 7300Prism Sequence
Detection System (Applied Biosystems, Foster City, CA). All
samples were carried out in triplicate (10 ng of total RNA per well)
and repeated at least twice. Controls without template or reverse
transcriptase were run in each experiment.
Western Blots
NSCLC cell lines were seeded in 10 cm Petri dishes at 56105
cells per dish, which resulted in 30–40% confluency 24 hours after
plating. Cells were harvested at 24 hours by adding trypsin,
pelleted and lysed in 100 ml of lysis buffer (NaCl 15 mM; EDTA
0.5 mM; Tris 10 mM) using a Branson Sonifier. Cell debris was
collected by centrifugation at 4uC, and protein concentration was
measured by the BCA method. Protein was resolved by SDS-
PAGE and was transferred to a nitrocellulose membrane. The
membrane was blocked with TBS with 5% nonfat powdered milk.
Membranes were immunoblotted with the following primary
antibodies: p120ctn (BD biosciences Cat. number 610133); E-
cadherin (BD biosciences Cat. number 61081); CRK II (Santa
Cruz Biotechnology Cat. number sc-289); p-Ser41 CRK-II (Santa
Cruz Biotechnology Cat. number sc-130186); PAK1 (Sigma-
Aldrich Cat. number SAB4300427) and c-Myc (Santa Cruz
Biotechnology Cat. number sc-40).
Horse radish peroxidase conjugated secondary antibodies were
used for detection of bands by chemiluminescence (ECL western
blotting detection reagents, Amersham Biosciences, Piscataway,
NJ, USA).
CRK Mutant Construct Generation and Stable Expression
We obtained a CRK-II expression plasmid (OriGene Technol-
ogies Cat. number RC201701). A sight directed mutagenesis kit
(Strategene Cat. number200523) was used according to the
manufacturer instructions in order to replace serine 41 with either
glycine or aspartic acid by replacing the corresponding nucleo-
tides. The following primer sets were used for site directed
mutagenesis.
N Ser41Gly Forward: 59-TCC TGG TGC GGG ACT CG-
G GCA CCA GCC CCG GGG ACT
ATG TGC-39
N Ser41Gly Reverse: 59-GCA CAT AGT CCC CGG GGC
TGG TGC CCG
AGT CCC GCA CCA GGA-39
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N Ser41Asp Forward: 59-TCC TGG TGC GGG ACT CG-
G ACA CCA GCC CCG GGG ACT
ATG TGC-39
N Ser41Asp Reverse: 59-GCA CAT AGT CCC CGG GGC
TGG TGT CCG AGT CCC GCA CCA
GGA-39
All constructs were checked by sequencing for accuracy of
mutagenesis. Subsequently, A549 cells were transfected with the
above mentioned plasmids by using Lipofectamine 2000 (Invitro-
gen). 24 hours after transfection, cells were treated with G418 at
1500 mg/ml in order to generate stable cell lines. The pooled
transfected and selected cells were used for the subsequent
experiments.
Wound Healing Assays and Microscopy
A549 and H157 cells were plated in a 6 well plate dish at 16105
cells per well and were grown to confluent stage. By using a sterile
P1000 pipette tip, a straight scratch was made along the largest
diameter of each well and a baseline photomicrograph was taken
from this scratch with two different magnifications. A follow up
photomicrograph was taken at 24 hours. Photomicrographs of the
cells were obtained by a Nikon Eclipse TS100 inverted microscope
equipped with a Cannon A510 digital camera. The digital camera
was connected with a Max View Plus adaptor (ScopeTronix) to
the inverted microscope. An equal area of the photomicrographs
from each condition was imported into the Adobe Photoshop
software and the resolution of the pictures were set at 25 pixels/
inch. The resulting low-resolution pictures were made of countable
squares pixels. The surface area of the wound in each condition
was measured by counting the number of pixels in each wound
area. Experiments were repeated three times and the average
wound surface area was compared among the groups.
Cell Invasion Assay
Matrigel cell invasion assays were performed by using Matrigel
Invasion Chamber (BD Biosciences Cat. number354480) accord-
ing to the manufacturer instructions. 16105 cells were incubated
in the upper chambers in RPMI in the absence of serum in
triplicates. As the chemoattractant, RPMI with 10% FBS was used
in the lower chambers. Cells were incubated for 24–36 hours in
the 37uC incubator. Cells were harvested and stained with Diff-
QuikTM kit according to the manufacturer’s instructions. Photo-
micrographs were taken by an Olympus BH2 microscope
equipped with a Cannon A510 digital camera. The invaded cells
in five corresponding regions of each Matrigel membrane were
counted and the mean of invaded cells were compared among the
groups.
Measurement of Cell Proliferation
Following plating equal number of A549 cells transfected with
CRK-II and CRK-II mutants in triplicates, cells were harvested at
24 hour intervals. Cells were stained by Trypan blue and counted
by using a hemocytometer.
Measurement of Western Blot Signal Intensity
A photograph of the western blots were imported into Adobe
Photoshop software. The photographs were inverted in order to
present the protein bands as the brighter signal compared to the
background. An equal area of each band was selected and the
mean and standard deviation of signal intensity were recorded by
the histogram tool of the software. In case the signal intensity of
any selected band was reaching the maximum range of the
histogram thereby causing signal saturation, the contrast of the
image was adjusted to avoid signal saturation.
Supporting Information
Figure S1 Western blots showing the endogenous CRK-
II and CRK-II-Myc mutants following transient trans-
fection of CRK-II-Myc mutant constructs in A549, Rh2,
and H157 cells. Measurement at 48 hours post transfection.
(TIF)
Figure S2 Western blots showing the endogenous CRK-
II and CRK-II-Myc mutants in A549 cells stably trans-
fected with CRK-II mutants. The endogenous CRK-II is
diminished by a CRK-II siRNA directed against a sequence
outside the open reading frame of CRK. The expression level of
CRK-II-Myc mutants as well as the endogenous CRK-II levels are
quantified and the ratio of CRK-II mutant/endogenous CRK-II
are demonstrated.
(TIF)
Figure S3 Wider views of wound healing assays pre-
sented in (Figure 3).
(TIF)
Figure S4 Wider views of the invasion assays presented
in (Figure 3).
(TIF)
Figure S5 Line chart representing the growth rate of
A549 cells stably expressing pCMV (empty vector), wild
type CRK-II (WT), CRK-II (Ser41Gly) or CRK-II (Ser41-
Asp) mutants.
(TIF)
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